December 2014

A recombinant FVIII Fc fusion protein product candidate for the treatment of hemophilia A is under review in Europe.

The US Food and Drug Administration recently announced it had received a submission for a biologics license application from Nektar Therapeutics and Baxter International Inc for an investigational, extended half-life recombinant factor VIII treatment for hemophilia A.

Stanford researchers were able to cure hemophilia in mice models using a new genome editing method. Their findings were published in Nature.

For mild hemophilia A patients, the risk of inhibitor development is higher than previously thought, according to findings published in the journal Blood.

Long-term relief for hemophilia B patients was achieved via adeno-associated virus treatments, according to findings published in The New England Journal of Medicine.

In mice models of hemophilia A, a modified tobacco plant diet was effective at prohibiting the development of inhibitors, according to research published in the journal Blood.